Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Anacor Pharma Says GSK Voluntarily Paused Enrollment Of Ongoing GSK '052 Trials

Anacor Pharmaceuticals Inc (ANAC: Quote) Monday announced that its partner GlaxoSmithKline (GSK) has voluntarily paused enrollment in its current clinical trials of GSK2251052.

Anacor further stated that GSK had recently identified microbiological finding in a small number of patients in the Phase 2b trial of GSK '052 for the treatment of complicated urinary tract infections.

GSK is in the process of obtaining additional information in order to better understand the data, but will not resume the trials until it has concluded its investigation. Upon completion of the review, GSK will determine next steps regarding the future development of GSK '052.

Click here to receive FREE breaking news email alerts for Anacor Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
After moving modestly higher in morning trading, stocks showed a substantial move to the downside over the course of the trading day on Wednesday. The major averages pulled back well off their highs for the session, sliding firmly into negative territory. Ebola "czar" Ron Kain is scheduled to meet with President Barack Obama on Wednesday as he begins his efforts to coordinate the government's response to the deadly disease. Klain, who previously served as chief of staff to Vice President Joe Biden and then-Vice President Al Gore, was named as Ebola Response Coordinator last Friday. Potentially complicating the outlook for control of the Senate, the results of a SurveyUSA poll conducted for WXIA-TV in Atlanta suggest that the Georgia Senate race between Republican David Perdue and Democrat Michelle Nunn could be headed for a runoff.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.